It’s only fair to share… Lomedeucitinib CAS 2328068-29-5 MF C18H172H3N6O4S MW 419.5 g/mol 4-{[3-(methanesulfonyl)pyridin-2-yl]amino}-N-(2H3)methyl-6-[(1R)-spiro[2.2]pentane-1-carboxamido]pyridazine-3-carboxamide 4-[(3-methylsulfonyl-2-pyridinyl)amino]-6-[[(2R)-spiro[2.2]pentane-2-carbonyl]amino]-N-(trideuteriomethyl)pyridazine-3-carboxamideJanus kinase inhibitor, anti-inflammatory, BMS-986322, BMS 986322, EYQ7KA55XA Lomedeucitinib is an investigational new drug that is being evaluated for the treatment of psoriasis and psoriatic arthritis. It is a tyrosine kinase 2 (TYK2) inhibitor.[1] SYN US20210253554 https://patentscope.wipo.int/search/en/detail.jsf?docId=US333829535&_cid=P10-MHIXWK-98212-1 General Scheme for Examples 252 and 253: Example 252 Step 1 A mixture …
Tag «Janus kinase inhibitor»
Girocitinib
It’s only fair to share… Girocitinib CAS 2222137-79-1 MFC17H18N4O3 MW 326.36 2-[(2R,5S)-5-[4-[(1R)-1-hydroxyethyl]-12-oxa-3,5,8-triazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,10-pentaen-3-yl]oxan-2-yl]acetonitrile [(2R,5S)-5-{2-[(1R)-1-hydroxyethyl]-1H-furo[3,2-b]imidazo[4,5-d]pyridin-1-yl}oxan-2-yl]acetonitrile 2-((2R,5S)-5-(2-((R)-1-hydroxyethyl)-1H-furo[3,2-b]imidazo[4,5-d]pyridin-1-yl)tetrahydro-2H-pyran-2-yl)acetonitrileJanus kinase inhibitor, anti-inflammatory, A0IES9T8GO In an era where targeted therapies are redefining the landscape of medical treatment, Girocitinib emerges as a beacon of hope for many. This innovative drug, developed by leading pharmaceutical research institutions, primarily targets specific proteins involved in disease progression. …
Frevecitinib
It’s only fair to share… Frevecitinib CAS 1299417-07-4 MF C22H21N7O2 MW 415.4 g/mol 3-[(3S)-3-(1-methyl-2-oxo-5-pyrazolo[1,5-a]pyridin-3-ylimidazo[4,5-b]pyridin-3-yl)piperidin-1-yl]-3-oxopropanenitrile 3-{(3S)-3-[1-methyl-2-oxo-5-(pyrazolo[1,5-a]pyridin-3-yl)-1,2-dihydro-3H-imidazo[4,5-b]pyridin-3-yl]piperidin1-yl}-3-oxopropanenitrileJanus kinase inhibitor, anti-inflammatory, 5N5L287M8T, KN 002, KN-002 Single and Multiple Ascending Dose Study of KN-002 CTID: NCT05006521 Phase: Phase 1 Status: Completed Date: 2024-08-07 SYN https://patentscope.wipo.int/search/en/detail.jsf?docId=US210080653&_cid=P11-MH2U9I-58146-1 It has now been found that a drug substance disclosed in WO2011/051452, namely the compound (S)-3-(3-(1-methyl-2-oxo-5-(pyrazolo[1,5-a]pyridine-3-yl)-1H-imidazo[4,5-b]pyridine-3(2H)-yl)piperidin-1-yl)-3-oxopropanenitrile having the structure …
Envudeucitinib
It’s only fair to share… Envudeucitinib CAS 2417135-66-9 MF C22H18[2]H6N6O3 MW426.5 g/mol N-[4-{2-methoxy-3-[1-(2H3)methyl-1H-1,2,4-triazol-3-yl]anilino}-5-(3,3,3-2H3)propanoylpyridin-2-yl] cyclopropanecarboxamide N-(4-(2-methoxy-3-(1-(trideuteriomethyl)-1,2,4-triazol-3-yl)anilino)-5-(3,3,3-trideuteriopropanoyl)pyridin-2-yl)cyclopropanecarboxamide N-[4-[2-methoxy-3-[1-(trideuteriomethyl)-1,2,4-triazol-3-yl]anilino]-5-(3,3,3-trideuteriopropanoyl)pyridin-2-yl]cyclopropanecarboxamideJanus kinase inhibitor, anti-inflammatory, Fronthera U.S. Pharmaceuticals, psoriasis, FTP 637 Envudeucitinib is an investigational new drug that is being evaluated for the treatment of psoriasis. It is a selective tyrosine kinase 2 (TYK2) inhibitor developed by Fronthera U.S. Pharmaceuticals LLC and now owned by Alumis, Inc. for …